“The Pink Sheet” Audio Summaries Podcast, July 2015

Audio news from “The Pink Sheet” includes health insurers’ reactions to drug valuation tools, concerns about the generic drug user fee program and FDA review of surrogate endpoints.

In this month’s “Pinkcast,” we highlight a couple of stories our writers covered on the FDA beat in recent weeks, including how FDA’s failure to spend much of the revenue generated through generic drug user fees are causing some gripes about the program, as well as CDER Director Janet Woodcock’s ideas about conducting centralized reviews of novel surrogate endpoints. We’ll also get into another big story: new tools for providers to gauge the value of oncology drugs.

Listen by clicking on Soundcloud below, or download the podcast direct from here.

Here are links to articles mentioned in the podcast:

• ASCO Value Framework Could Inform Clinical Pathways, Payers Say
• ASCO Value Framework Presents ‘Net Health Benefit’ Score For Drugs
• NCCN’s Cancer Treatment Guidelines To Add Drug Cost Considerations
• FDA's GDUFA War Chest Grows, And Industry May Look For Lower Fees
• FDA Central Review Likely For Novel Surrogate Endpoints